Kartha Pharmaceuticals Inc.
Plan context: Kartha Pharmaceuticals Inc. Retirement Plan
EIN 32-0432815 • 7 filings • 1 plans
Current Snapshot
Latest Year
2024
2024 Participants
1
2024 Assets
$553
2024 Contributions
$461,137
Historical Graphs
Total Assets Over Time
Aggregate end-of-year assets by filing year, excluding zero-asset years
Participants Over Time
Largest reported end-of-year plan headcount by filing year, used to avoid double-counting participants across overlapping plans
Company Timeline
Year summaries and individual filings are combined here so you can stay in one place while moving across years and plan filings.
| Year / Filing | Filings | Participants | Assets | Contributions | Contrib./Participant |
|---|---|---|---|---|---|
| 2024 | 1 | 1 | $553 | $0 | - |
| Kartha Pharmaceuticals Inc. Retirement Plan | - | 1 | $553 | - | - |
| 2023 | 1 | 1 | $133,891 | $0 | - |
| Kartha Pharmaceuticals Inc. Retirement Plan | - | 1 | $133,891 | - | - |
| 2022 | 1 | 2 | $296,091 | $0 | - |
| Kartha Pharmaceuticals Inc. Retirement Plan | - | 2 | $296,091 | - | - |
| 2021 | 1 | 2 | $296,091 | $0 | - |
| Kartha Pharmaceuticals Inc. Retirement Plan | - | 2 | $296,091 | - | - |
| 2020 | 1 | 2 | $271,498 | $0 | - |
| Kartha Pharmaceuticals Inc. Retirement Plan | - | 2 | $271,498 | - | - |
| 2019 | 1 | 3 | $525,016 | $0 | - |
| Kartha Pharmaceuticals Inc. Retirement Plan | - | 3 | $525,016 | - | - |
| 2018 | 1 | 3 | $500,015 | $461,137 | $153,712iApproximate average salary by contribution assumption: employee only about $3,842,808 at 4% or $2,561,872 at 6%; with 50% employer match about $2,561,872 at 4% or $1,707,915 at 6%; with 100% employer match about $1,921,404 at 4% or $1,280,936 at 6%. |
| Kartha Pharmaceuticals Inc. Retirement Plan | - | 3 | $500,015 | $461,137 | $153,712iApproximate average salary by contribution assumption: employee only about $3,842,808 at 4% or $2,561,872 at 6%; with 50% employer match about $2,561,872 at 4% or $1,707,915 at 6%; with 100% employer match about $1,921,404 at 4% or $1,280,936 at 6%. |